Hao Oubo (688656.SH) released semi-annual results, with net profit of 16.6776 million yuan to mother, an increase of 37.05% over the previous year

According to Zhitong Finance App News, Hao Oubo (688656.SH) disclosed the 2026 semi-annual report. During the reporting period, the company achieved operating income of 196 million yuan, an increase of 3.22%; net profit attributable to shareholders of listed companies was 16.6776 million yuan, an increase of 37.05% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 153.308 million yuan, an increase of 47.99% year on year; basic earnings per share were 0.27 yuan.

The company continues to cultivate the Hainan Free Trade Port and the Guangdong-Hong Kong-Macao Greater Bay Area's “Pharmaceutical Device Connect” policy area, increasing investment in the Odek marketing of desensitizing drugs, driving revenue growth of 116.83%; the overseas market expansion of the diagnostic testing business has achieved remarkable results, and overseas sales revenue increased 38.11% year on year; the domestic diagnostic business was under pressure, and revenue fell slightly by 0.49%.